> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# SpringWorks Therapeutics Awarded Priority Voucher
- URL: https://www.fdaweb.com/springworks-therapeutics-awarded-priority-voucher/
- Published: 2025-03-13T12:00:00.000Z
- Updated: 2026-09-14T14:55:18.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5158817

*Federal Register* notice: FDA is announcing that a priority review voucher was issued to SpringWorks Therapeutics for achieving a 2/11 NDA approval for Gomekli (mirdametinib) for treating adults and pediatric patients two years of age and older with neurofibromatosis Type 1 who have symptomatic plexiform neurofibromas. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2025-03-13/pdf/2025-04021.pdf?ref=fdaweb.com).